Welcome to our dedicated page for Mirion Technologies news (Ticker: MIR), a resource for investors and traders seeking the latest updates and insights on Mirion Technologies stock.
Mirion Technologies, Inc. reports company developments in radiation detection, measurement, analysis and monitoring solutions for nuclear, medical, defense and research markets. Updates commonly cover financial results, orders, guidance, investor presentations and leadership appointments across the Nuclear & Safety and Medical groups.
Mirion's recurring business themes include nuclear power customers, critical radiation safety applications, R&D labs, nuclear facilities and healthcare uses such as Nuclear Medicine, Radiation Therapy QA, Occupational Dosimetry and Diagnostic Imaging. News also reflects the completed Paragon Energy Solutions acquisition, which added engineered nuclear-power offerings and is being integrated into the Nuclear & Safety group.
Mirion Technologies (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at the Goldman Sachs Industrials and Materials Conference on May 10, 2022, at 11:20 AM ET in New York, NY. The presentation will be available for live streaming on their website, with an archived version accessible for two weeks after the event. Mirion Technologies specializes in detection and monitoring solutions across various sectors, including nuclear and defense, and operates in 13 countries.
Mirion Technologies, Inc. (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at Wells Fargo’s 2022 Industrials Conference on Thursday, May 5, 2022, at 12:00 PM ET in New York, NY.
The presentation will be webcast live and accessible at Mirion's website, where it will be archived for two weeks following the event. Mirion provides detection, measurement, analysis, and monitoring solutions across various sectors, employing around 2,600 people globally.
Mirion Technologies (NYSE: MIR) will release its financial results for the first quarter of 2022 on May 4, 2022, followed by a conference call at 11:00 am ET. Participants can join by calling 1-844-826-3033 or 1-412-317-5185. A live webcast will also be available at Mirion's Investor page. A telephonic replay will be accessible until May 18, 2022. Mirion is a leader in detection, measurement, and analysis solutions for various markets, including nuclear and medical, employing around 2,600 people across 13 countries.
Mirion Technologies (NYSE: MIR) has announced an upgraded Cloud-hosted, SaaS option for its SunCHECK™ Quality Management Platform. This platform enhances workflows for Radiation Therapy Quality Assurance, improving patient safety and reducing operational burdens. The SaaS model offers better scalability and reliability, utilizing Amazon Web Services for infrastructure. Over 1,600 users currently utilize SunCHECK software, showcasing its significance in cancer care. The SaaS solution is designed to meet diverse clinic needs and will be demonstrated at ESTRO 2022 in Copenhagen.
Mirion Technologies reported a 18% increase in revenue for Q4 2021, totaling $177.8 million, compared to $150.8 million in Q4 2020. The company posted a GAAP net loss of $23.0 million for the same period. Adjusted EBITDA rose to $44.5 million, up from $31.2 million in the previous quarter. For the fiscal year 2022, Mirion forecasts adjusted revenue growth between 5.5% and 7.5% and adjusted EBITDA of $175 million to $185 million. The company is facing supply chain challenges but remains confident in its growth prospects.
Mirion Technologies, Inc. (NYSE: MIR) announced that CEO Thomas Logan and CFO Brian Schopfer will present at the Citi Global Industrial Tech and Mobility Conference in Miami, FL, on February 24, 2022, at 1:50 PM ET. The presentation will be webcast live, with an archived version available afterward. Mirion is a premier provider of detection and monitoring solutions for nuclear, defense, and medical sectors and operates in 13 countries, employing around 2,600 people. For additional details, visit Mirion.com.
Mirion Technologies, Inc. (NYSE: MIR) will release its financial results for the fourth quarter and fiscal year ended December 31, 2021 on February 23, 2022. A conference call to discuss these results will take place on the same day at 10:00 am ET. Investors can join by calling 1-877-407-9208 or via webcast at Mirion's investor relations website. A telephonic replay will be available until March 9, 2022.
Kaman Composites – Vermont, a subsidiary of Kaman Corporation (NYSE:KAMN), has partnered with Mirion Technologies (NYSE:MIR) to expand its medical imaging program. This collaboration involves Kaman supplying surgical C-Arm tabletops, with the first deliveries scheduled for Q2 2022. Kaman Composites possesses 40 years of expertise in designing composite components and is recognized for its rigorous manufacturing standards. This partnership signifies Kaman's growing presence in the medical technology sector while maintaining its aerospace industry role.
Sun Nuclear Corporation, a subsidiary of Mirion Technologies (NYSE: MIR), has announced the full program for the 2022 QA & Dosimetry Symposium (QADS), scheduled for April 8-9 in Orlando, Florida. The event will focus on Quality and Patient Safety in Radiation Oncology, featuring six session themes and over 20 presentations. Topics include Cybersecurity in Healthcare and Practical Dosimetry. Notably, the symposium will address challenges posed by cyberattacks and the COVID-19 pandemic. Registration is open until January 21, 2022.
Mirion Technologies (NYSE: MIR) has launched the Hyperion™ Compact Digital High Radiation Tolerant Camera, available in color and monochrome versions. This innovative camera enhances digital performance while reducing the cost of ownership, making it ideal for surveillance and high radiation environments, including nuclear power plants. The Hyperion Compact boasts improved durability, significant performance advancements, and a total integrated dose specification of 100 megarads. This development underscores Mirion's commitment to growth in the nuclear power sector.